Straumann Group (STMN) Q4 2024 earnings summary

Executive summary

• Achieved 13.7% organic revenue growth in 2024, reaching CHF 2.5 billion, with Q4 organic growth at 11.5% and strong performance in EMEA, APAC, and Latin America, and stabilization in North America.

• Expanded global market share in implantology, moving from 32% to 35%, and gained share in both premium and value segments.

• Launched iEXCEL premium implant system and SIRIOS intraoral scanner, with positive clinician feedback and global rollout.

• Employee engagement score reached 82, placing in the top 10% globally, with a 92% participation rate.

• Board proposes a dividend increase to CHF 0.95 per share, with a payout ratio of about 30%.

Financial highlights

• Full-year revenue CHF 2.5 billion, 13.7% organic growth, 10% in CHF after currency headwinds.

• Core EBIT margin at 26% (CHF), or 27.6% at constant FX; core net profit CHF 502 million, margin 20%.

• Free cash flow CHF 373 million (14.9% of revenue); cash position CHF 375 million; debt CHF 200 million.

• Basic core EPS CHF 3.14, up 15% FX-adjusted; IFRS EPS CHF 2.87.

• Core gross margin 71.4%, down 240 bps currency-adjusted, mainly due to FX, portfolio mix, and China VBP.

Outlook and guidance

• 2025 outlook: high single-digit organic revenue growth and 30–60 bps core EBIT margin improvement at constant 2024 FX.

• Ongoing investments in capacity, digital transformation, and clinician training to support growth.

• Growth ambition for 2030 confirmed, with stable patient flow expected despite market uncertainties.